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Cellular communication is an essential process for the development and maintenance of all tissues including the eye. Recently, a
new method of cellular communication has been described, which relies on formation of tubules, called tunneling nanotubes
(TNTs). These structures connect the cytoplasm of adjacent cells and allow the direct transport of cellular cargo between cells
without the need for secretion into the extracellular milieu. TNTs may be an important mechanism for signaling between cells
that reside long distances from each other or for cells in aqueous environments, where diffusion-based signaling is challenging.
Given the wide range of cargoes transported, such as lysosomes, endosomes, mitochondria, viruses, and miRNAs, TNTs may
play a role in normal homeostatic processes in the eye as well as function in ocular disease. This review will describe TNT
cellular communication in ocular cell cultures and the mammalian eye in vivo, the role of TNTs in mitochondrial transport with
an emphasis on mitochondrial eye diseases, and molecules involved in TNT biogenesis and their function in eyes, and finally,
we will describe TNT formation in inflammation, cancer, and stem cells, focusing on pathological processes of particular interest
to vision scientists.
1. Introduction
Cells have numerous mechanisms of communication in
order to develop normally, repair wounds, and respond to
inflammation. Many of these mechanisms rely on secretion
of signals from one cell, diffusion through the extracellular
milieu, and uptake by a target cell, which may be located
far from the secretory cell. An excellent synopsis of morpho-
gen signaling was recently published, which uses a “drunken
sailor” analogy to comprehensively describe the current
models, hypotheses, and challenges of diffusion-based signal-
ing processes (Figure 1) [1]. Two more recent modes of com-
munication are also described: cytonemes and tunneling
nanotubes (TNTs) (Figure 2). These cellular structures allow
signaling over long distances by providing direct connections
between cells, which overcomes many challenges of
diffusion-based signaling [2–7]. While cytonemes have been
described in the Drosophila imaginal eye disc [8], nothing is
known of their existence in the vertebrate eyes. Conversely,
there is a burgeoning literature on TNTs since their first
description in 2004 [2]. TNTs are specialized filopodia that
transport signals directly between cells. TNTs are composed
of an actin core, although microtubules may also be involved
in certain cell types [9]. Due to continuity of cytoplasm
within the tube, larger cargo can be trafficked than could be
shared via gap junctions [10–14]. LysoTracker-labeled vesi-
cles were the first organelles shown to be transported from
one cell to an adjacent one [2]. Other groups subsequently
showed the intercellular transfer of mitochondria and
endocytic vesicles derived from early endosomes, the Golgi
complex, endoplasmic reticulum, and lysosomes [15–20].
In addition, TNTs are involved in the spread of pathogens
such as viruses, prions, and bacteria [12, 18, 21–23] and other
small molecules such as miRNAs, Ca2+, calcein, Lucifer yel-
low, and quantum dot nanoparticles [11, 24–29]. However,
there appears to be some selectivity in the cargo that is
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transferred because some TNTs support transfer of electrical
signals, while other cell types do not [10, 30]. Thus, TNTs
may be responsible for communicating cellular signals that
previously were thought to have been mediated by diffusion.
There are several excellent reviews that provide in-depth
discussion on TNT biogenesis [11, 19, 30, 31]. Two current
biogenesis models are the cell dislodgement and the actin-
driven models [2, 3, 25]. In the former, two adjacent cells in
close proximity form short tubes, which are drawn out as
the cells move apart. In the actin-driven model, filopodia
extend from two adjacent cells and when their tips touch,
they fuse to form a single conduit. As the name implies, this
latter mechanism depends on actin. Several molecules are
also implicated in TNT formation, including M-Sec, myo-
sin-Va, myosin-X, synaptophysin, Rho GTPases (cdc42,
Rac1), RASSF1A, LST1, and Rab8/Rab11a [25, 32–39].
This review will detail the current knowledge of the exis-
tence and potential role of TNTs in ocular homeostasis and
disease pathogenesis. We will first describe (1) the current
knowledge of TNTs in the mammalian eye, (2) the role of
TNTs in mitochondrial transfer with an emphasis on eye dis-
ease, (3) TNTmolecular regulators and their function in eyes,
and (4) the role of TNTs in other diseases that are of interest
to vision researchers.
2. TNTs and Cytonemes in the Eye
2.1. TNTs in Corneal Tissue. A few years following the first
reports of TNTs in in vitro settings, Chinnery et al. described
the presence of long (up to 300 microns), thin (<1 micron)
membrane extensions protruding from MHC Class II-
positive immune cells in the mouse cornea (Figure 3) [40].
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Figure 1: Morphogen transport and the drunken sailor analogy. (a) The transport of morphogens from a source establishes a gradient in the
target field. (b–h) Five major morphogen transport models are illustrated using the drunken sailor analogy, in which drunken sailors move by
random walks from a ship into a city. In this analogy, morphogen molecules are represented by sailors and cells are represented by buildings.
(b) In the case of free diffusion, sailors (green dots) leave the ship (blue oval) and disperse into the city (white square). Inset: sailors take steps
of the indicated fixed size, and the direction of each step is random. This “random walk” describes the diffusive behavior of molecules in
solution. (c) In the tortuosity-mediated hindered diffusion model, buildings (gray) act as obstacles that sailors must move around, thus
increasing the tortuosity of the environment. (d) In the case of diffusion that is hindered by tortuosity and transient binding, the sailors
stop in pubs (negative diffusion regulators, yellow) located at the periphery of buildings. Note that, in contrast to effects from tortuosity
alone, sailors congregate at the periphery of buildings, and there are relatively few freely moving sailors. (e, f) The shuttling model does
not require a localized source of sailors. Instead, sailors are initially present mostly in pubs (negative diffusion regulators, yellow) and
uniformly distributed in the city (e). Police officers (positive diffusion regulators, red) disperse from a source on the right side, pick up
sailors from pubs, and escort them through the city by preventing further pub visits (f). When police officers disappear (not shown),
sailors can reenter the pubs. Over time, this results in the concentration of sailors on the left. (g) In the transcytosis model, the sailors
travel through the buildings. (h) During directed transport-mediated by cytonemes, the sailors travel through subway tunnels (orange),
which deposit the sailors in buildings (reproduced from Muller et al. (2013) with no alterations under the Creative Commons Attribution
4.0 International license (http://creativecommons.org/licenses/by/4.0/)) [1].
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The transparent tissue environment of the corneal stroma,
with its unique arrangement of collagenous lamellae and
absence of pigmentation, likely enabled the first visualization
of these elusive cellular structures in a mammalian tissue.
Unlike other tissues such as the skin, where resident tissue
macrophages and dendritic cells are abundant (approxi-
mately 1000 cells/mm2) [41], the density of immune cells in
the cornea is comparatively low (100-150 cells/mm2) [42].
Thus, intercellular communication between widely spaced
cells in the cornea may be facilitated by the presence of long
cellular extensions. In a follow-up study, membrane nano-
tubes were also identified in the mouse dura mater, which
is another dense connective tissue that shares similar struc-
tural features with the cornea [43]. Using time-lapse confocal
microscopy, nanotube formation in the mouse cornea was
dynamically visualized in corneal explants from macrophage
GFP reporter mice, with evidence supporting de novo forma-
tion, with an average speed of 15μm/minute.
While the first two reports of TNTs in the mammalian
cornea were novel, insights into their proposed function or
role in disease were not provided. In a study exploring the
potential for treating corneal pathology associated with the
lysosomal storage disease, cystinosis, Rocca and colleagues
performed a hematopoietic progenitor stem cell transfer
from healthy wild-type donor mice into cystinosin gene-
deficient animals (ctns-/-) [44]. In addition to improving
the clinical outcome of ocular pathology, such as corneal
thinning and elevated IOP, transfer of transplanted cystino-
sin lysosomes from healthy donor cells into diseased, recipi-
ent cells was observed in corneal macrophages. Macrophage-
mediated transfer of healthy cystinosin lysosomes to diseased
fibroblasts via TNTs was also demonstrated in vitro [45].
These studies provide compelling evidence that damaged
intracellular organelles can be “rescued” by transplantation
of healthy donor cells, with TNTs serving as conduits for
delivery of the healthy cargo.
2.2. TNTs in the Trabecular Meshwork. The trabecular mesh-
work (TM) is a small, circumferential, sieve-like tissue
located in the anterior segment of the eye. The TM regulates
aqueous humor outflow from the anterior chamber and thus
establishes intraocular pressure (IOP) [46]. When outflow is
disrupted, due to blockages in the TM outflow channels, IOP
begins to increase. Elevated IOP is a primary risk factor for
glaucoma, a leading cause of blindness worldwide [47]. TM
cells sense changes in IOP and communicate signals to
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Figure 2: Cytonemes and tunneling nanotubes. (a) Cytonemes were originally identified in Drosophila imaginal discs but have also been
detected in developing chick limb buds. These cellular structures transport ligands and receptors over long distances from one cell to another
in the complex tissue environment. Ligands cluster at the tip of a cytoneme and interact with clustered receptors on the surface of the
recipient cell. (b) Tunneling nanotubes (TNTs) transport cellular organelles such as mitochondria, endosomes, and lysosomes, as well as
other cargoes such as viruses, prions, and Ca2+ signals. TNTs form a tube through which these cargoes are directly transported between cells.
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remodel the extracellular matrix to allow greater aqueous
fluid flow and alleviate pressure. However, signaling in this
aqueous environment is challenging because signals secreted
from the cell are immediately diluted in aqueous humor fluid,
which can drain into Schlemm’s canal before reaching their
target cell. Furthermore, cells in the putative stem cell region
of the tissue, posterior to Schwalbe’s line, are not bathed in
aqueous humor [48]. Yet, we know that these cells must
receive signals because they are induced to migrate into the
TM in response to burns placed by laser trabeculoplasty, a
common treatment to relieve elevated IOP in glaucoma
patients [49]. It is currently unclear how signals released at laser
sites can be transported long distances (>100μm) at high
enough concentrations to elicit their effects at the insert region.
This suggests additional mechanisms must be employed by TM
cells to communicate signals in an aqueous environment.
TNTs formed by cultured TM cells were first described
by Keller et al., in 2017 (Figure 4) [50]. In this study, live cell
imaging showed the transfer of DiO fluorescently labeled
vesicles and mitochondria from one TM cell to another. Over
the course of 40 minutes, four vesicles were transferred.
Using various manipulations of the actin cytoskeleton, a
Rho kinase inhibitor, Y27632, increased the number of vesi-
cles transferred, while inhibition of the Arp2/3 complex with
CK-666 reduced vesicle transfer [50]. When glaucoma TM
cells were compared to normal TM cells, TNTs were less
abundant, but they were longer [51]. Also, the actin cytoskel-
eton was less dynamic in GTM cells and it appeared that
transfer may be bidirectional since both DiO- and DiD-
labeled vesicles were present in the same TNT. A greater
number of GTM cells contained vesicles of the opposite color
compared to normal TM cells, suggesting that a more stabi-
lized actin cytoskeleton could lead to prolonged TNT con-
nections, which, combined with possible bidirectional
vesicle transfer, would account for the increased transfer over
time. Together, these data provided the first evidence that
normal and glaucomatous TM cells utilize TNTs to commu-
nicate with each other.
2.3. TNTs in the Retina. The retinal pigment epithelium
(RPE) is a monolayer of pigmented cells that provides meta-
bolic support to the photoreceptors in the retina. TNTs have
been detected in cultured RPE cells [52]. In these cells, TNTs
transferred mitochondria, endosomes, and Ca2+. Transfer of
Ca2+ indicates that the TNTs were electrically coupled, which
was confirmed by the localization of connexin 43+ gap junc-
tions at the tips of TNTs connecting RPE cells [52]. However,
gap junctions cannot transfer larger molecules so another
mechanism must exist for organelle transfer. As well as
RPE cell communication, TNTs may also play a role in
angiogenesis in the retina. A recent study showed that vascu-
lar endothelial growth factor (VEGF) and hypoxia-inducible
factor-1α (HIF-1α) signals can be transferred between malig-
nant ovarian cancer cells and human vascular endothelial
cells (HUVEC) [53]. The authors speculated that TNTs could
stimulate angiogenesis by propagating these potent angio-
genic factors. If similar studies showed that VEGF and
HIF-1α were transported by TNTs in retinal cells, a new tar-
get for anti-VEGF treatments for diabetic retinopathy, reti-
nopathy of prematurity, and/or wet age-related macular
degeneration may be revealed.
Pericytes are mesenchymal-derived cells that encircle
endothelial cells of capillaries in the microvasculature.
Together with astrocytes and neurons, they form a neurovas-
cular unit that functions to maintain the blood-brain and
blood-retina barrier [54]. Retinal pericytes are lost in diabetic
retinopathy patients, making retinal capillaries vulnerable to
proliferation signals and formation of leaky neovessels which
can lead to blindness [55]. In the brain, pericytes form TNTs,
which appear to function in probing the environment for
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Figure 3: TNTs connecting inflammatory macrophages adhering to
the corneal endothelium. (a) Confocal Z-stack of Iba-1+ (red)
CD68+ (green) macrophages on the posterior surface of the
corneal endothelium in mice one week after topical exposure to
synthetic DNA, which causes accumulation of keratic precipitates
[136] (asterisks denote nuclei of the endothelial cell monolayer).
Interconnecting cytoplasmic TNTs are clearly visible between
some of the macrophages (b, inset of dashed box in a), with
punctate intracellular CD68+ signal visible between two cells
(arrows; which represent approximately 3 μm distance from the
endothelium). (c) Rotated view of Z-stack showing nanotube
connecting the two cells (white arrow in c), which appears above
the layer of the endothelium (blue arrow in c). Scale bar is 25 μm.
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other cells as well as communicating signals during brain
development and during pathological neovascularization
[56]. The role of pericyte-derived TNTs in the retina is an
unexplored target to prevent abnormal angiogenesis, which
underpins the pathogenesis of several blinding diseases affect-
ing the retina.
2.4. Cytonemes in the Drosophila Eye. Like TNTs, cytonemes
are specialized filopodia with an actin core (Figure 2). How-
ever, instead of forming a tube through which cargo is
carried, signals travel along the surface of the cytoneme [7].
Cytonemes were first described by Ramirez-Weber and
Kornberg in 1999, who studied decapentaplegic signaling in
the Drosophila wing imaginal disc [6]. Later studies investi-
gated epidermal growth factor (EGF) signaling in the Dro-
sophila eye disc and found that epithelial cytonemes, which
express the EGF receptor, orient themselves toward the mor-
phogenetic furrow, where the Spi/EGF-producing cells are
(a) (b)
(c) (d)
(g)(f)(e)
Figure 4: Cellular protrusions formed by ocular trabecular meshwork (TM) cells. (a, b) The cell membrane of TM cells was labeled with CD44
antibodies (cyan), and vesicles were labeled with DiO (green) or DiD (red). DiD-labeled vesicles are clearly observed in a TNT connecting to a
DiO-labeled cell. (c, d) A long cellular protrusion (130 μm) extends between two TM cells in culture (CD44 immunostaining = green;
SiR-actin = red). At higher magnification, the tips of the protrusion are not fused to form a continuous tunnel so this structure may be a
cytoneme. (e–g) TM cells were labeled with DiO (e; green) or with MitoTracker (f; red) and CD44 cell membrane immunostaining (cyan).
Red mitochondria are transferred into a DiO-labeled cell via TNTs. Scale = 20 μm.
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located [8]. Thus, cytonemes extend long distances (up to 20
cell diameters) to link EGF producing and receiving cells,
which provides specificity in signaling over long distances
in tissues [57]. To date, there are no descriptions of
cytonemes in the vertebrate eye. Recent reviews describe
the similarities and differences between cytonemes and TNTs
in more detail [58, 59].
3. Mitochondrial Intercellular Transfer via
TNTs and Implications for Eye Diseases
Mitochondrial dysfunction in ocular disease is relatively
common, especially in genetic disorders that disrupt their
structure or function [60]. Mutations in OPA1 and MFN2
genes cause autosomal dominant optic atrophy (DOA);
mutations in WFS1 and CISD2 can cause Wolfram syn-
drome, while Leber’s hereditary optic neuropathy (LHON)
is associated with mutations in mitochondrial ND1, ND4,
and ND6 genes [61, 62]. However, many other eye diseases
have been linked to mitochondrial dysfunction occurring
secondary to other conditions including glaucoma and other
optic neuropathies, age-related macular degeneration, dia-
betic retinopathy, and retinitis pigmentosa [63–71].
Intercellular transfer of mitochondria can occur via
TNTs, and it appears to be a common occurrence in cell cul-
tures and possibly in vivo [72, 73]. Mitochondria are ATP
generators, and they are essential for cell survival. The trans-
fer of mitochondria between cells was first observed in cocul-
ture experiments where healthy mitochondria from human
mesenchymal stem cells were transferred via cytoplasmic
projections to A549 cells, which have defective or depleted
mtDNA [74]. Several subsequent studies suggested that
intercellular transfer of mitochondria is linked to cell survival
[16, 17, 75–77]. For instance, Liu et al. [16] showed that mes-
enchymal stem cell-derived mitochondria rescued oxida-
tively stressed human umbilical vein endothelial cells
(HUVECs) from apoptosis. Other groups have suggested that
TNT-mediated transfer could induce differentiation of mes-
enchymal stem cells into renal tubule cells [27], while mito-
chondrial transfer in cocultures of endothelial cells and
cancer cells conveyed chemoresistance to the cancer cells
receiving the mitochondria [78]. Transcellular mitochondrial
exchange is not limited to cells in culture with new evidence
showing that this process can also occur in vivo where
healthy mitochondria were transferred from astrocytes to
neurons in the mouse brain [76]. This transfer was CD38-
dependent and led to a neuroprotective effect after stroke.
While these in vitro and in vivo studies show mitochondrial
transfer between heterotypic cell types, other groups describe
mitochondrial transfer between homotypic cell types [20, 50,
79]. For instance, Wang and Gerdes demonstrated that mito-
chondria transferred from untreated, healthy PC12 to UV-
stressed PC12 cells reversed the early stages of apoptosis [20].
Little is known about the molecules that are involved in mito-
chondrial trafficking, but Miro1 appears to be involved [80].
A role for mitochondrial transfer in ocular cells is emerg-
ing. In the cornea, mitochondria were transferred via TNTs
in cocultures of corneal epithelial cells and mesenchymal
stem cells [81]. When MSCs were applied to the corneas of
rabbits with alkali burns, mitochondria were transferred to
the host corneas. However, it could not be determined
whether this transfer was via TNTs or whether it was due to
release of mitochondria into the extracellular space for uptake
by neighboring cells. In retinal ARPE-19 cells, mitochondria
and endocytic organelles were found within the TNT connec-
tions [52]. With this discovery, the authors suggested that
mitochondria may be transferred between themselves or
hypothetically between RPE cells and photoreceptors [52].
While RPE cell culture experiments show TNTs, TNTs in ret-
ina tissue in vivo have not yet been reported. This is likely due
to their fragility upon fixation and lack of a good biomarker.
However, one study hints at their existence. Transcellular
mitochondrial exchange between neurons and glia in the optic
nerve head (ONH) was recently described [82]. In this study,
serial block-face scanning electron microscopy demonstrated
that mitochondria shed from ONH-resident neurons were
engulfed and degraded by lysosomes in neighboring astro-
cytes. It is possible that direct connections via TNTs were
involved in this mitochondrial transfer, but the thin tubules
may have been destroyed during the harsh fixation treatments
used in the preparation procedures used for electron micros-
copy. While speculative, studies such as these are highlighting
the importance of intercellular transfer of mitochondria and
TNTs as a potential mechanism of transfer.
4. Molecular Regulation of TNTs in the Eye
Several molecules play a role in TNT biogenesis, and some of
these have roles in various physiological processes in the eye.
For instance, Rab8a/Rab11a and myosin-Va, which are asso-
ciated with TNTs [2, 37], have been found to be involved in
normal photoreceptor signaling in the retina [83, 84]. In
Xenopus and zebrafish photoreceptors, Rab8a/Rab11a are
involved in transporting rhodopsin from the Golgi to the dis-
tal inner segment membranes, the first step before intrafla-
gellar transport to the outer segment. However, the role of
Rab8a/Rab11a in the mammalian eye appears more complex
since they are dispensable for the transport of rhodopsin to
the mouse outer segment [84]. Further studies are needed
to resolve the contribution of these proteins to TNT biogen-
esis and normal homeostatic processes in the eye. However,
one TNT regulator, myosin-X (Myo10), appears to play a
major role in TNT-mediated processes in the eye, which we
will now describe in more detail.
4.1. Myo10 Background. Several groups have described a role
of Myo10 in filopodia and TNT formation [85–87]. Myo10
belongs to a group of four unconventional myosins—Myo7a,
Myo7b, Myo10, and Myo15a—which, unlike conventional
myosins, do not form filaments and are not involved in mus-
cle contraction [88]. Myo10 was first described by Berg et al.
[89] and is localized to areas of dynamic actin reorganization.
It is composed of an actin-binding head domain, a neck
domain, and a tail domain, which is involved in binding of
cargo and dimerization [90]. The head domain of Myo10
binds to F-actin and acts as a molecular motor, hydrolyzing
ATP to transport itself along the actin filaments. The head
domain is essential for this transport since “headless”
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recombinant constructs do not travel along filopodia [91].
Some cell types such as neurons express an endogenous
“headless” Myo10, which negatively regulates full-length
Myo10 [92, 93]. The neck domain of Myo10, which contains
IQmotifs, may regulate the motor activity of the head domain
or increase flexibility of the molecule as it walks hand-over-
hand along actin filaments [94]. The tail domain offers
diversity from the other unconventional myosins and is com-
posed of a coiled-coil region, three PEST domains, three PH
domains, a myosin tail homology 4 (MyTH4), and a band
4.1, ezrin, radixin, moesin (FERM) domain [90]. The coiled-
coil domain is important for dimer formation. The antiparallel
coiled-coil structure of Myo10 dimers is optimized tomove on
actin bundles rather than single actin filaments [95]. The
MyTH4 and FERM domains in the tail domain also bind sev-
eral different molecules including microtubulin, β-integrin,
and the VE-cadherin complex [96–98].
4.2. Myo10 Role in Filopodia and TNT Formation. Overex-
pression of Myo10 in a variety of cell types increases the
number of filopodia emanating from the cell surface, while
Myo10 knockdown reduces filopodia number [85, 86, 91,
99, 100]. Overexpression of Myo10, but not VASP or fascin,
also induced TNT formation [87]. Other studies show that
Myo10 appears to play multiple roles in filopodia/TNT for-
mation including at the initiation and elongation phases
[86, 101]. Shorter filopodia predominated when the C-
terminal FERM domain was eliminated [86]. Live cell imag-
ing using GFP-tagged Myo10 constructs shows Myo10 in
bright puncta at the filopodia tips and along the length of
the cellular protrusion [90, 91]. Fainter Myo10 clusters were
also apparent along the filopodial shaft. The bright puncta
travel at around 80nm/second, while the faint Myo10 moves
even faster at around 600 nm/sec [90]. Myo10 also undergoes
retrograde movement but at much slower speeds of
15 nm/sec, a rate that is similar to the retrograde flow of actin
[102]. There is some controversy of whether Myo10 moves
faster on actin filaments or bundles [95, 103, 104]. Differ-
ences may be due to the origin of actin bundles used in each
study, i.e., fascin-induced actin bundles versus nascent filo-
podia, which presumably contain additional actin-binding
proteins. Together, these studies demonstrate that Myo10
plays a critical role in TNT biogenesis, elongation, and cargo
transport.
4.3. Eye Phenotypes Caused by Myo10 Knockdown and
Knockout. Myo10 is expressed in the retina and the TM
[105–107]. Recent RNAi knockdown studies and knockout
mouse models have revealed functional roles for Myo10 in
the eye. In an anterior eye study, RNAi silencing lentivirus
was generated to selectively knock downMyo10 in TM tissue
and cells [107]. First, Myo10 silencing lentivirus was applied
to an ex vivo organ culture perfusion model to examine the
effects on outflow and IOP regulation [107]. Outflow rates
were significantly reduced suggesting that Myo10-mediated
filopodia/TNTs play a role in IOP regulation. In Myo10-
silenced TM cell cultures, matrix metalloproteinase activity
was reduced, consistent with a reduction in focal remodeling
of the extracellular matrix components of the outflow resis-
tance. Of note, Myo10 protein distribution in glaucomatous
TM tissue was disrupted compared to age-matched normal
tissue [51].
Two Myo10 knockout mouse models were recently
described, and both have posterior chamber ocular pheno-
types (Figure 5) [105, 106]. The first knockout model ablated
both full-length and headless forms of Myo10 [105]. Between
embryonic days E12.5 and E17.5, approximately 60% of
Myo10 knockout mice exhibited exencephaly, a lethal neural
tube closure defect. However, 40% of homozygotes survived
to adulthood. Of these survivors, all exhibited a white belly
spot and persistent fetal vasculature (PVF) in the eye
(Figures 5(a) and 5(b)). Other less penetrant phenotypes
included kinked tails and soft tissue syndactyly of the digits.
The bilateral persistent hyaloid vasculature in the posterior
eye was phenotypically similar to the human disease PVF.
In normal mice, the hyaloid vasculature develops around
E12.5 and is resorbed soon after birth (2-3 weeks). In
Myo10 knockout mice, hyaloid regression was dysfunctional
and a thin strand, which emanated from the optic disc,
extended through the vitreous, and connected to the poste-
rior lens, persisted. Retinal angiogenesis was also delayed in
Myo10-/- mice. Analysis of the retina using the endothelial
biomarker, PECAM-1, showed that the retinal vascular net-
work was less dense, and the endothelial cells had 50% less
filopodia (Figure 5) [105]. Other eye defects such as embry-
onic microphthalmia, anophthalmia, an optic fissure closure
defect, cloudy cornea, and lens spots were noted, but these
were sporadic [105].
A second Myo10 knockout mouse was developed, which
selectively knocked out the full-length Myo10 molecule, the
actin-binding form, but “headless” Myo10 expression was
unaffected [106]. Similar to the complete Myo10 knockout,
persistent hyaloid vasculature, white belly spots, and syndac-
tyly were common, but there was a reduced rate of exence-
phaly (24%) (Figure 5(c)). Surprisingly, there was no
vascularization defects noted despite Myo10 being the most
strongly expressed unconventional myosin in retinal vascular
endothelial cells. This selective knockout shows that full-
length Myo10 is important for hyaloid regression, but not
retinal vascularization. Together, these mouse models indi-
cate that Myo10 is required for normal embryonic develop-
ment and is important for filopodia formation in vivo.
5. Role of TNTs in Diseases Relevant to
Vision Research
In addition to their potential role in ocular disease, TNTs are
involved in many other pathological disease processes. Sev-
eral recent review papers provide discussion of TNTs in
health and disease in greater detail [39, 108–111]. Here, we
review the role of TNTs in several pathological processes of
particular interest to vision scientists.
5.1. Inflammatory Responses. Acute and chronic inflamma-
tion underpins a wide variety of ocular diseases, which can
have both local and systemic origins. Inflammation is a known
stimulator of TNT formation in immune cells [40, 112], but the
precise functional significance of this is unclear. Theoretically,
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Figure 5: Phenotype of twoMyo10 knockout mouse models. tm1d completely ablated all Myo10 forms, whereas tm2 selectively knocked out
the full-length, actin-binding Myo10, but “headless” Myo10 expression was unaffected. (a) Fluorescence image of flat mounted retinas
showing retinal vasculature at P5. Dissected retinas were stained with a PECAM-1 antibody (green) and counterstained with phalloidin
(red). The retinal vasculature extended to similar positions in the control and Myo10tm1d/tm1d eyes. The image represents a stitch of
micrographs taken at 20x and is best visualized if the images are enlarged on a digital display. (b) High-resolution images of the
angiogenic expansion front from the P5 retinas in (a) showing filopodia radiating from endothelial tips cells. Loss of Myo10 results in a
decreased number of filopodia and leads to a less dense vascular network. Images were captured as Z-stacks at 60x and displayed as
maximum projections with the PECAM-1 channel displayed in inverted grayscale to highlight endothelial filopodia. (c) High-resolution MRI
(magnetic resonance imaging) of enucleated and fixed eyes from adult wild-type (WT) and Myo10tm2/tm2 mice, where representative of 6 eye
scans for each genotype reveals persistence of the hyaloid vasculature in mutant mice. The hyaloid artery emerges from the optic disc and
extends toward the lens, as schematically illustrated on the right. Scale bars: 1mm (reproduced from (a, b) Heimsath et al. 2017 and (c)
Bachg et al. 2019 under the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/)) [105, 106].
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TNT could be exploited in vivo to deliver immunomodulat-
ing proteins that could inhibit or promote inflammation,
depending on the therapeutic need. In a study on the feasi-
bility of synthetic nanotubes as a drug delivery system, pep-
tide nanotubes were designed to deliver Caspase-3 siRNA as
a means to inhibit keratocyte apoptosis in the injured mouse
corneal stroma [113]. While this study was based on exoge-
nous nanotube delivery to the wounded cornea, it does pro-
vide evidence that nanotube-mediated transfer of therapeutic
siRNA could occur in vivo. In vitro evidence suggests that
when fibroblasts are cocultured with TGF-β1-stimulated den-
dritic cells, membrane nanotube formation increases. Fur-
thermore, tenascin-C, a proregenerative extracellular matrix
molecule, was localized to the TNTs [114], suggesting that
exposure to certain growth factors can promote the forma-
tion of TNTs between fibroblasts and possibly contribute to
tissue remodeling. Whether the delivery of drugs or therapies
aimed at suppressing ocular inflammation could also apply
to biological TNTs, either through donor cell transfer or by
upregulating endogenous TNT formation in vivo, is a largely
unexplored and exciting future area of research.
5.2. Cancer. Several studies have investigated the role of
TNTs in cancer (reviewed in [111]). Of particular interest
to vision researchers is the role of the tumor suppressor gene,
RASSF1A, in uveal melanomas [115]. RASSF1A binds cyto-
skeletal proteins such as actin and microtubules, playing an
important role in TNT formation, cell cycle regulation, and
apoptosis to maintain cellular homeostasis [35, 111]. Loss
of RASSF1A gene expression is observed in certain cancers,
including uveal melanomas in the eye [115, 116]. In malig-
nant mesothelial cell lines, downregulation of RASSF1A
increased the number of TNT connections, while overexpres-
sion decreased the TNT number and length [35]. Thus,
increased TNT-mediated communication concomitant with
downregulation of RASSF1A appears linked to cancer pro-
gression. RASSF1A is downregulated in uveal melanoma
tumors as well as in uveal melanoma cell lines [115]. There-
fore, it seems plausible that TNT communication is involved
in uveal melanomas.
5.3. Stem Cells. Therapeutic stem cell transplantation is a hot
area of vision research. Recent evidence suggests that stem
cells may not necessarily integrate as functioning cells but
rather exert a local trophic influence to regenerate host cells
[117]. In vitro studies have reported the transfer of mito-
chondria and other cellular organelles between heterotypic
cell types such as mesenchymal stem cells and endothelial
cells [16, 17, 45, 75, 81, 118–120]. Many of these studies also
describe that formation of TNT connections “rescues” dying
cells. In the cornea, hematopoietic stem progenitor cells
(HSPCs) were transplanted into cystinosin-null mice and
these were found to home to the cornea to restore normal
corneal structure and function [44]. Interestingly, some of
these HSPCs differentiated into macrophages, which formed
TNTs that appeared to transport cystinosin-containing lyso-
somes into adjacent diseased cells. Thus, control of TNTs
may provide a novel mechanism to transport normal pro-
teins to diseased cells in lysosomal storage diseases [121].
Transplantation of stem cells has also been suggested as a
therapeutic option for glaucoma [48, 122]. Stem cells may
provide a source of factors that promote survival of resident
cells or modulate the intraocular microenvironment. Mesen-
chymal stem cell (MSC) transplantation has shown to be
neuroprotective for RGCs [122], andMSCs offer an attractive
therapeutic option for repopulating the cells of the TM of
POAG patients, which have a marked reduction in the TM
cell number [123]. Several groups have shown that introduc-
tion of MSCs [124], or induced pluripotent stem cells (iPSCs)
[125–127], may restore TM IOP regulation function. In both
anterior and posterior glaucoma stem cell therapies, it is con-
ceivable that TNTs formed between stem cells and resident
cells could promote survival of the remaining endogenous
host cells. Further studies are required to explore these
possibilities.
6. Future Perspectives: Potential Applications of
TNTs in Ocular Therapies
A growing area of ocular research concerns the delivery of
drugs and gene therapies [128–131]. Many papers have
described the use of nanoparticles as drug delivery systems,
which offer attractive advantages over conventional methods
including targeted delivery, increased drug bioavailability
with lower doses, sustained release, and reduced side effects
[132]. Nanoparticles can be used to deliver a variety of
payloads such as ocular gene therapies, contrasts agents for
bioimaging, nanodrugs, and/or antimicrobial agents [133].
He et al. reported that quantum dots made from CdSe/ZnS
(15-20 nm diameter) were rapidly internalized by cardiac
myocytes and were transported bidirectionally via TNTs
[24]. Subsequently, other researchers showed that nanoparti-
cles made from porous silicon (3.2μm diameter) were
directly transferred between cells via TNTs [134]. These
studies in other tissues of the body suggest that TNTs may
be used to deliver nanoparticles to specific tissues in the eye.
Viruses can spread via TNTs [7], which could be
exploited to deliver viral-mediated gene therapies in the
eye. Recently, the first gene therapy, Luxturna, received
FDA approval. This modified, inactive AAV2 virus is deliv-
ered by subretinal injection to replace defective RPE65 in
children with Leber’s congenital amaurosis [135]. Since
RPE cells in vitro communicate via TNTs [52], it is conceiv-
able that TNTs could be utilized to provide more effective
delivery of virus-mediated gene therapies to targeted photo-
receptor cells in the retina. However, multiple challenges
remain and more research is needed to reveal how TNTs
can be manipulated to form de novo to ensure efficient trans-
port of the nanoparticles or viruses in vivo.
7. Final Thoughts
The current knowledge of TNTs in specific ocular tissues is
summarized in Figure 6. While the discovery of TNTs has
challenged existing dogma and opened up new avenues for
research into how cells communicate, there are still many
outstanding questions that need to be addressed. Studies on
signals, mechanisms, and/or microenvironments that initiate
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their creation, as well as determining the molecules involved
in their elongation, stability, and collapse, will likely yield
novel ways that we can control TNTs. Improvements in
high-resolution, intravital imaging techniques and develop-
ment of specific fluorescent reporter mice will enable further
investigation into the physiology of TNT formation in ocular
tissues in vivo. Targeted inhibition of key proteins, or RNA
silencing of genes involved in TNT formation, in specific tis-
sues and cell populations will also lead to further understand-
ing of the function of TNTs during ocular homeostasis and
during disease. This should open new avenues of research
to design novel therapies for the treatment of a wide range
of eye diseases.
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